Small interfering RNA (siRNA) holds transformative potential for sequence-specific gene silencing, yet its clinical translation has been hindered by delivery barriers. Naked siRNA cannot cross cell membranes, is rapidly degraded by serum nucleases, and accumulates in endosomal compartments rather than reaching the cytoplasm where the RNA-induced silencing complex (RISC) operates. Cell-penetrating peptides (CPPs) offer a solution by forming covalent conjugates that ferry siRNA across biological barriers without viral vectors or lipid nanoparticles. The design of effective CPP-siRNA conjugates requires coordination of peptide selection, conjugation chemistry, and endosomal escape mechanisms to achieve meaningful gene knockdown. This article examines the design principles governing CPP-siRNA conjugates, compares the delivery performance of major CPP families, and outlines optimization strategies for in vivo applications. For a broader overview, visit our Peptide-RNA Conjugation service page.
The field of CPP-mediated oligonucleotide delivery has matured from non-covalent electrostatic complexes to well-defined covalent conjugates with reproducible stoichiometry and improved pharmacokinetics. Covalent CPP-siRNA conjugates eliminate the variability inherent in self-assembling nanoparticle formulations, enabling dose-dependent gene silencing with predictable pharmacology. The choice of CPP sequence, linker chemistry, and endosomolytic augmentation profoundly influence whether a conjugate reaches its target mRNA or remains trapped in endosomal vesicles. Our Peptide-siRNA Conjugation platform provides tailored solutions for each of these design considerations.
siRNA is a 21-23 nucleotide duplex with a net negative charge of roughly -40 at physiological pH, rendering it essentially impermeable to the phospholipid bilayer. Even when siRNA enters cells via endocytosis, it faces endosomal entrapment. Following internalization, siRNA traffics through early endosomes, late endosomes, and lysosomes, where acidic pH and hydrolytic enzymes degrade the duplex before it can engage RISC. Studies consistently report that less than 2% of internalized siRNA escapes from endosomal compartments, making endosomal release the rate-limiting step for gene silencing efficacy. These dual barriers, membrane impermeability and endosomal trapping, define the fundamental challenge that CPP-siRNA conjugates must overcome.
CPPs are short peptide sequences, typically 5-30 residues, that traverse cell membranes through endocytic pathways and, in some cases, direct translocation. When covalently attached to siRNA, the CPP converts the anionic duplex into a construct with reduced net negative charge, enabling electrostatic interactions with the negatively charged cell surface. This facilitates adsorptive endocytosis without exogenous transfection reagents such as cationic lipids. Unlike Lipofectamine-based formulations that disrupt membrane integrity, CPP-siRNA conjugates rely on receptor-independent uptake across diverse cell types. The absence of carrier lipids simplifies manufacturing and eliminates lipid-associated toxicity. Researchers can explore our CPP Synthesis capabilities for the peptide synthesis foundations of these sequences.
Early CPP-siRNA strategies relied on non-covalent electrostatic complexation, where cationic CPPs were mixed with siRNA to form self-assembling nanoparticles. These complexes achieved gene silencing in cell culture but suffered from stoichiometric ambiguity, serum instability, and unpredictable biodistribution. The electrostatic bonds dissociate in the presence of serum proteins, releasing naked siRNA before reaching target cells. Covalent conjugation eliminates this instability by forming a permanent or conditionally cleavable linkage, ensuring the two components remain associated throughout circulation, cellular uptake, and endosomal transit. Covalent CPP-siRNA conjugates also permit precise characterization by HPLC and mass spectrometry, enabling batch consistency and regulatory compliance. Modern Peptide-oligonucleotide Conjugation platforms reflect this evolution from non-covalent to covalent formats.
The CPP landscape encompasses diverse sequence families with distinct mechanisms of membrane penetration and endosomal escape. Understanding the structure-activity relationships of each CPP class is critical for selecting the optimal carrier peptide for a given siRNA target. The table below summarizes the key properties of four major CPP families used in siRNA delivery.
| CPP Family | Net Charge at pH 7.4 | Primary Mechanism | siRNA Delivery Efficiency (In Vitro) | Key Limitation |
| Tat (YGRKKRRQRRR) | +9 | Adsorptive endocytosis with partial direct translocation | 50-70% gene knockdown at 200-500 nM | Low endosomal escape,<2% cytosolic release |
| Penetratin (RQIKIWFQNRRMKWKK) | +7 | Amphipathic membrane insertion and endocytosis | 60-80% gene knockdown at 100-400 nM | Serum protein binding reduces activity |
| Oligoarginine R9 | +9 | Macropinocytosis-mediated uptake | 70-85% gene knockdown at 100-300 nM | High charge causes membrane toxicity at >5 uM |
| PepFect14 (Stearyl-RLRRRRR) | +7 | Stearyl-modified amphipathic CPP with enhanced endosomal release | 80-95% gene knockdown at 50-200 nM | Stearyl group increases non-specific binding |
Table 1. Comparative Properties of Major CPP Families for siRNA Delivery
Cationic CPPs derive their activity from clusters of positively charged residues, primarily arginine and lysine. The HIV-1 Tat peptide was the first CPP shown to deliver nucleic acids into cells, and its arginine-rich domain remains a benchmark. Tat-mediated siRNA uptake occurs through adsorptive endocytosis, binding heparan sulfate proteoglycans on the cell surface. Oligoarginine sequences, particularly R8 and R9, provide higher charge density and more efficient macropinocytic uptake. Polylysine-based CPPs offer an alternative scaffold, but lysine lacks the guanidinium group that enables bidentate hydrogen bonding with membrane phosphates, resulting in lower translocation efficiency. Haque et al. demonstrated that the DG9 peptide, with optimized arginine spacing, achieves superior oligonucleotide delivery compared to Tat at lower cytotoxicity, illustrating how charge distribution governs performance.
Amphipathic CPPs combine cationic and hydrophobic domains, enabling simultaneous electrostatic binding and hydrophobic membrane insertion. Penetratin, derived from the Antennapedia homeodomain, contains a tryptophan-rich hydrophobic core flanked by arginine residues. PepFect peptides represent engineered amphipathic CPPs with a fatty acid moiety conjugated to the N-terminus, enhancing membrane affinity and endosomal escape. PepFlect14 achieves near-complete gene silencing at sub-micromolar concentrations, surpassing Tat and R9 by two to fourfold. NickFect derivatives further optimize the scaffold by incorporating pH-sensitive histidine residues that promote endosomal disruption under acidic conditions. Malinowska et al. reviewed the chemistry underlying these engineered sequences and their peptide-oligonucleotide conjugation applications.
Endosomal escape remains the principal bottleneck for CPP-siRNA conjugates, and fusogenic peptide domains exploit the pH gradient between the extracellular environment (pH 7.4) and late endosomes (pH 5.0-5.5). The influenza hemagglutinin HA2 peptide undergoes a pH-triggered conformational change to an amphipathic helix at pH 5.0, inserting into the endosomal membrane and creating transient pores. GALA, a glutamic acid-alanine-leucine-alanine repeat peptide, similarly transitions to a membrane-destabilizing helix at acidic pH. Modern CPP designs fuse these fusogenic domains to the carrier sequence, creating bifunctional peptides for uptake and release. Nakamura et al. demonstrated that combining an RNA-binding peptide with an endosomal escape-assisting peptide enhanced cytosolic siRNA delivery by an order of magnitude, establishing this dual-domain architecture as a defining feature of next-generation conjugates.
The chemical linkage between the CPP and siRNA determines whether the conjugate remains intact during circulation, releases the payload at the correct intracellular location, and avoids premature degradation. Three principal strategies each offer distinct pharmacological advantages.
Disulfide bonds exploit the dramatic difference in glutathione concentration between the extracellular space (2-20 uM) and the cytoplasm (1-10 mM). In circulation, the disulfide remains stable. Upon escape into the cytosol, millimolar glutathione rapidly reduces the disulfide, releasing siRNA from the CPP and enabling the duplex to load into RISC without steric interference. Tat-siRNA and R9-siRNA disulfide conjugates achieve significantly higher gene silencing than permanently linked counterparts because free siRNA engages RISC more efficiently. The reduction kinetics can be tuned by incorporating sterically hindered cysteine residues, slowing cytosolic release to match endosomal escape kinetics and maximize RISC loading.
When permanent CPP attachment is required, thiol-maleimide and copper-free click chemistry provide robust conjugation options. Thiol-maleimide coupling between a CPP-terminal cysteine and a maleimide-functionalized siRNA forms a stable thioether bond resisting glutathione reduction and intracellular proteases. This linkage is advantageous when the CPP domain contributes to RISC assembly or enhances siRNA stability. Click chemistry approaches, particularly strain-promoted azide-alkyne cycloadditions using DBCO or BCN cyclooctynes, offer superior specificity and yield without copper catalysts that could damage RNA. Researchers can consult our Click Chemistry service for protocol guidance and scale-up options.
Bifunctional CPPs integrate a cell-penetrating domain and an endosomolytic domain within one peptide chain, simplifying conjugation because only one peptide must be synthesized and coupled to siRNA. A representative design attaches an R9 domain for uptake to an HA2 or GALA domain for endosomal escape, with a glycine spacer preserving independent conformational dynamics. The bifunctional approach enables tissue targeting when the CPP incorporates a homing sequence for specific cell types, such as tumor-homing tLyP-1 or muscle-targeting M12 peptides. The linker between CPP and siRNA can be independently optimized, using a disulfide bond for cytosolic release while the bifunctional CPP handles uptake and endosomal disruption. Design principles for these constructs are available on our Peptide Linker Design resource page.
Endosomal escape is the rate-limiting step for CPP-siRNA efficacy, with 95-98% of internalized conjugates remaining trapped in endosomal compartments. Understanding the mechanisms by which CPPs disrupt endosomal membranes is essential for designing therapeutically effective conjugates.
The proton sponge hypothesis posits that cationic peptides with buffering capacity between pH 5 and 7 accumulate in endosomes, accept protons from the V-ATPase pump, and cause chloride influx, osmotic swelling, and eventual rupture. Arginine-rich CPPs contribute through guanidinium buffering, but the proton sponge effect accounts for only a small fraction of release because nine arginine residues have modest buffering capacity compared to polymeric carriers. The primary mechanism involves electrostatic binding to anionic phospholipids, displacing resident proteins and creating transient pores. This electrostatic disruption achieves cytosolic release rates below 5%, explaining why cationic CPPs without fusogenic augmentation produce modest in vivo silencing.
Amphipathic CPPs exploit the endosomal pH gradient more efficiently. Penetratin and PepFect derivatives undergo pH-triggered conformational transitions that increase membrane-destabilizing activity at endosomal pH. At neutral pH, the CPP maintains a disordered conformation with limited membrane insertion. Upon acidification to pH 5.0-5.5, protonation of glutamic acid and histidine triggers alpha-helical folding, exposing the hydrophobic face and creating membrane-spanning pores. This pH-selective mechanism minimizes membrane damage extracellularly while maximizing disruption at endosomal pH. PepFlect14 and NickFect5 achieve 10-15% endosomal escape efficiency, approximately three to five times higher than Tat. Gait et al. documented that addition of a pH-responsive sequence increased functional cytosolic delivery by an order of magnitude in CPP-conjugated splice-switching oligonucleotides.
Quantifying endosomal escape involves subcellular compartment redistribution rather than a simple concentration measurement. Split-fluorescent protein assays attach a GFP fragment to the conjugate and express its complementary fragment in the cytosol. Escape produces cytosolic GFP fluorescence quantifiable by flow cytometry, while trapped conjugates remain non-fluorescent. Chloroquine wash experiments artificially release trapped conjugate, with the resulting silencing increase attributed to the endosomal fraction. Triton X-100 fractionation separates cytosolic from membrane-bound material for qPCR measurement. Live-cell imaging with pHrodo enables real-time tracking of trafficking and cytosolic arrival. These methods collectively reveal that escape efficiency varies from 1% for Tat to 15% for optimized bifunctional CPPs, providing measurable benchmarks for design optimization.
Different CPP families produce widely varying gene silencing outcomes when conjugated to the same siRNA, reflecting differences in uptake mechanism, endosomal escape, and intracellular stability. Direct comparisons provide guidance for selecting the optimal CPP for a given application.
| CPP-siRNA Conjugate | Target Gene | Cell/Tissue Model | Max Knockdown (%) | Effective Dose Range | Endosomal Escape Fraction |
| Tat-siRNA (disulfide) | GAPDH | HeLa cells | 55-70% | 200-500 nM | 1-3% |
| Penetratin-siRNA (disulfide) | Luciferase | HeLa cells | 65-80% | 100-400 nM | 4-8% |
| R9-siRNA (disulfide) | GAPDH | HeLa cells | 75-85% | 100-300 nM | 3-5% |
| PepFlect14-siRNA | Luciferase | HeLa cells | 90-95% | 50-200 nM | 10-15% |
| R9-HA2-siRNA (bifunctional) | BACE1 | Primary neurons | 60-75% | 200-500 nM | 8-12% |
| tLyP1-R9-siRNA | VEGF | MDA-MB-231 xenograft | 50-65% | 2-5 mg/kg i.v. | 5-10% (estimated) |
Table 2. Gene Silencing Efficiency of CPP-siRNA Conjugates Across Cell Types and Target Tissues
Head-to-head comparisons consistently rank R9 as the most effective cationic CPP for in vitro silencing, followed by Penetratin and Tat. In HeLa cells, R9-siRNA achieves 75-85% knockdown at 100-300 nM, while Tat-siRNA requires 200-500 nM for 55-70%. R9 superiority derives from higher charge density and macropinocytic uptake delivering a larger endosomal payload. Penetratin occupies an intermediate position, benefiting from amphipathic membrane insertion. In serum-containing media, Penetratin-siRNA activity declines due to hydrophobic interactions with albumin, while R9-siRNA retains activity up to 10% serum. In primary neurons and cardiomyocytes, Penetratin achieves better uptake, likely because amphipathic peptides interact more effectively with lipid-rich neuronal membranes. These tissue-dependent differences highlight the importance of empirical CPP screening.
PepFlect and NickFect represent second-generation CPPs engineered to overcome endosomal escape limitations. PepFlect14 combines a stearyl lipid anchor with an arginine-rich core, creating an amphipathic construct with pH-triggered membrane destabilization. The stearyl group increases membrane binding by an order of magnitude, and PepFlect14-siRNA achieves 90-95% knockdown at 50-200 nM, four to ten times lower than Tat or R9 require. NickFect5 and NickFect6 incorporate histidine-rich domains combining the proton sponge mechanism with amphipathic disruption for synergistic release. These engineered CPPs maintain >80% silencing activity in 50% serum compared to<30% for Tat-siRNA. The design principles, including lipidation, histidine insertion, and non-natural amino acid substitution, provide a roadmap for further CPP engineering.
CPP-siRNA performance varies substantially across tissue types. In skeletal and cardiac muscle, cationic CPPs such as R9 achieve robust silencing because muscle cells exhibit high macropinocytosis rates. R9-siRNA targeting dystrophin exon sequences achieves 50-70% exon skipping in mdx mouse muscle at 5-10 mg/kg intramuscular doses. In the CNS, amphipathic and bifunctional CPPs perform better because neuronal membranes favor amphipathic peptide insertion. R9-HA2-siRNA targeting BACE1 produces 60-75% knockdown in primary cortical neurons, sufficient to reduce amyloid beta production in Alzheimer models. In tumor tissue, acidic extracellular pH enhances uptake of pH-responsive CPPs, and tumor-homing motifs such as tLyP-1 achieve selective accumulation. tLyP1-R9-siRNA targeting VEGF reduces tumor vascularization by 50-65% in MDA-MB-231 xenografts at 2-5 mg/kg, demonstrating tissue-specific CPP design enables therapeutically meaningful in vivo silencing.
Translating CPP-siRNA conjugates from cell culture to in vivo applications requires addressing three interconnected challenges: toxicity reduction, circulation time extension, and serum stability enhancement.
Cationic CPPs at concentrations above 5-10 uM cause dose-dependent membrane perturbation and cell death, and similar toxicity emerges at systemic doses above 5 mg/kg in mice. Sequence truncation offers a straightforward strategy: shortening R9 to R7 or R6 decreases net charge while preserving most uptake activity. Charge modulation through arginine-to-lysine substitution reduces guanidinium density, though it also decreases uptake efficiency. A more sophisticated approach alternates arginine with non-charged residues such as beta-alanine, creating "charge-spaced" CPPs that maintain total charge while reducing local charge density. DG9, with optimized arginine spacing, achieves oligonucleotide delivery comparable to R9 at half the cytotoxicity. Researchers can leverage our CPP Synthesis platform for these truncated and charge-modulated sequences.
Unmodified CPP-siRNA conjugates exhibit rapid renal clearance and extensive non-specific binding, resulting in plasma half-lives below 30 minutes. PEGylation addresses both limitations by increasing hydrodynamic radius above the renal filtration threshold and shielding the cationic CPP from anionic serum components. Short PEG chains (2-5 kDa) reduce non-specific binding while preserving cellular uptake. Longer PEG chains (20-40 kDa) extend circulation to 2-6 hours but can attenuate uptake by encapsulating the CPP domain. Branched PEG architectures offer an intermediate solution, combining high shielding efficiency with maintained CPP exposure. PEGylated conjugates also display reduced liver and spleen accumulation, improving the fraction of injected dose reaching target tissues.
Serum nucleases degrade unmodified siRNA within minutes. CPP attachment provides partial protection by electrostatic shielding, but chemical modification of the siRNA strand, including 2'-O-methyl, 2'-fluoro, and phosphorothioate substitutions, dramatically increases nuclease resistance while preserving RISC compatibility. Phosphorothioate modification at terminal positions increases serum half-life from minutes to hours. The CPP itself must resist proteolytic degradation, achieved through D-amino acid substitution, retro-inverso design, or terminal acetylation/amidation. D-arginine CPPs (r9) retain the same activity as L-arginine R9 but exhibit serum protease stability exceeding 24 hours. The combination of nuclease-resistant siRNA and protease-resistant CPP design produces conjugates with plasma stability sufficient for systemic dosing.
CPP-siRNA conjugates have demonstrated gene silencing efficacy in preclinical models spanning muscular dystrophy, neurodegenerative disorders, and cancer, validating the platform across therapeutic domains with distinct tissue barriers.
Duchenne muscular dystrophy (DMD) results from dystrophin mutations that disrupt the reading frame. Exon skipping using splice-switching oligonucleotides (SSOs) restores the frame, producing truncated but partially functional dystrophin. CPP-conjugated SSOs targeting exon 23 in mdx mice achieve 50-70% exon skipping in skeletal muscle at 5-10 mg/kg intramuscular doses. Cardiac delivery has proven more challenging, but Pip6-series CPPs achieve 30-40% exon skipping in mouse heart at 15-25 mg/kg intravenous doses. Gait et al. demonstrated that CPP-conjugated SSOs with endosomal escape domains produce exon skipping in both skeletal and cardiac muscle at systemic doses, a critical advance for treating DMD where cardiac dysfunction drives mortality. These results establish CPP-SSO conjugates as viable alternatives to naked phosphorothioate oligonucleotides for muscular dystrophy.
The blood-brain barrier (BBB) excludes macromolecules from the brain, making CNS gene silencing one of the most demanding delivery challenges. Certain CPPs, particularly Penetratin and Tat, have demonstrated limited brain penetration following systemic administration. Bifunctional CPPs combining a BBB-crossing domain with an endosomal escape domain achieve neuronal silencing at 5-10 mg/kg intravenous doses, with R9-HA2-siRNA targeting BACE1 producing 60-75% knockdown in mouse cortical neurons and reducing amyloid beta by 40-50%. The BBB crossing mechanism involves transcytosis across brain endothelial cells. Intranasal administration bypasses the BBB entirely, delivering conjugates via olfactory epithelium axonal transport. Intranasal Penetratin-siRNA achieves 70-80% knockdown in the olfactory bulb and 40-50% in deeper brain structures at 1-2 mg/kg.
Oncology applications focus on silencing oncogenes, angiogenesis drivers, and drug resistance genes in tumor tissue. Tumor-homing CPPs such as tLyP-1, iRGD, and LyP-1 incorporate CendR motifs (R/KXXR/K) that trigger neuropilin-1-mediated tissue penetration after tumor vasculature binding. tLyP1-R9-siRNA targeting VEGF reduces tumor microvessel density by 50-65% in MDA-MB-231 xenografts, decreasing growth rate by 40%. iRGD-R9-siRNA targeting KRAS achieves 55-70% knockdown in patient-derived pancreatic tumor xenografts, producing tumor shrinkage at 3-5 mg/kg. These tumor-homing CPPs exploit the CendR transcytosis pathway constitutively active in tumor vasculature but not in normal tissue, providing selectivity that purely cationic CPPs lack. The combination of tumor homing, cell penetration, and endosomal escape in a single sequence represents the current frontier of CPP-siRNA design for oncology.
Regulatory-compliant development requires rigorous analytical characterization to confirm stoichiometry, purity, and functional activity. The hybrid peptide-RNA structure presents unique analytical challenges distinct from pure peptide or pure oligonucleotide therapeutics.
Reversed-phase HPLC with ion-pairing mobile phases separates CPP-siRNA conjugates from unconjugated siRNA and free peptide. Hexafluoroisopropanol-based phases provide superior resolution for peptide-oligonucleotide conjugates compared to triethylamine-based systems. LC-MS confirmation requires high-resolution mass spectrometry measuring the conjugate molecular weight (15-25 kDa) with accuracy below 5 ppm. Intact mass measurement confirms 1:1 stoichiometry and detects incomplete conjugation, while tandem MS fragmentation verifies the conjugation site and linker identity. These methods are essential for batch release and regulatory documentation, and our Peptide-oligonucleotide Conjugation analytical services provide validated protocols for CPP-siRNA characterization.
Cellular uptake quantification uses fluorescently labeled conjugates measured by flow cytometry or confocal microscopy to determine internalized fraction and subcellular distribution. Trypan blue quenching and acid wash protocols remove surface-bound material for accurate internalization measurement. Gene silencing dose-response curves, generated by treating cells with increasing conjugate concentrations and measuring mRNA knockdown by qRT-PCR or protein reduction by western blot, provide the definitive functional readout. The dose-response reveals potency (IC50), maximum efficacy (Emax), and dose-dependent toxicity. Standardized functional assays across multiple cell lines, including primary cells relevant to the target disease, are recommended before advancing to animal models.
Serum stability testing incubates conjugate in plasma at 37 degrees Celsius, sampling at intervals to measure intact conjugate by HPLC. Unmodified conjugates exhibit plasma half-lives of 5-30 minutes, while chemically modified conjugates achieve 2-8 hours. Disulfide linker stability in plasma is assessed by measuring intact versus released siRNA fractions, confirming no premature reduction by plasma thiols. Intracellular stability testing in 5 mM glutathione at pH 7.4 simulates cytoplasmic conditions, measuring siRNA release kinetics: typically 5-30 minutes for standard disulfide bonds and 1-4 hours for hindered variants. These profiles must match the endosomal escape timeline. Premature release wastes siRNA in endosomes, while excessively slow release delays RISC loading. Matching linker stability to intracellular trafficking is a critical design parameter.
Developing a CPP-siRNA conjugate from concept to preclinical validation requires specialized expertise in peptide synthesis, oligonucleotide chemistry, and conjugation methodology. The synthetic challenges include producing CPP sequences with non-natural amino acids, D-residue substitutions, lipid modifications, and bifunctional architectures, all exceeding standard peptide synthesizer capabilities. Conjugation chemistry demands orthogonal conditions that avoid RNA degradation while achieving quantitative yield, and characterization requires ion-pairing HPLC and high-resolution mass spectrometry validated for hybrid peptide-RNA molecules.
Creative Peptides provides an integrated platform spanning CPP design, synthesis, conjugation, purification, and analytical verification. Our peptide team produces cationic, amphipathic, and bifunctional CPPs with lipidation, PEGylation, and D-amino acid modifications at research and GMP scales. Our oligonucleotide chemistry group synthesizes siRNA with phosphorothioate, 2'-O-methyl, and 2'-fluoro modifications at researcher-specified positions. Conjugation specialists execute disulfide, thiol-maleimide, and click chemistry coupling with validated protocols and quantitative yield. Analytical services include purity confirmation by ion-pairing HPLC, stoichiometry verification by high-resolution LC-MS, and functional testing by cellular uptake and gene silencing assays. Whether you need a single conjugate for proof-of-concept experiments or a multi-gram batch for preclinical studies, our team delivers with the precision regulatory submissions require. Explore our full Custom Conjugation Service for tailored CPP-siRNA solutions.
The path from CPP-siRNA design to functional gene silencing involves iterative optimization across peptide selection, linker chemistry, siRNA modification, and formulation. Creative Peptides accelerates this cycle with rapid synthesis turnaround, analytical feedback within days, and design consultation based on published CPP-siRNA performance data. Our experience with Tat, R9, Penetratin, PepFlect, and bifunctional CPP conjugates enables informed recommendation of the optimal carrier peptide for your target tissue and disease model. We also offer scale-up from milligram research quantities to gram-level preclinical production with consistent quality. To discuss your CPP-siRNA conjugate project, please contact us directly for a detailed technical consultation and project timeline.
CPP-siRNA conjugates are internalized primarily through endocytic pathways, including macropinocytosis, clathrin-mediated endocytosis, and caveolae-mediated uptake, depending on the CPP sequence and cell type. Following internalization, the conjugate must escape from the endosomal compartment to reach the cytoplasm, where siRNA is loaded into the RNA-induced silencing complex (RISC). Endosomal escape is the rate-limiting step for most CPP-siRNA constructs and is the primary focus of CPP engineering efforts.
No single CPP is universally optimal; effectiveness depends on the target cell type, tissue, and siRNA cargo. Tat and oligoarginine (R8, R9) are widely used for their robust uptake across many cell types. Penetratin offers improved endosomal escape in some contexts. Engineered CPPs such as PepFect and NickFect incorporate pH-responsive and endosomolytic motifs that significantly improve cytoplasmic delivery over first-generation CPPs. Empirical screening of a small CPP panel is recommended for each new target.
The disulfide linker serves as a controlled-release mechanism: it remains stable in the oxidizing extracellular environment but is cleaved by the reducing environment of the cytoplasm (1-10 mM glutathione). This releases free siRNA from the CPP after endosomal escape, ensuring that the siRNA can be efficiently loaded into RISC without steric hindrance from the attached peptide. Non-cleavable linkers generally produce lower gene silencing activity because the CPP remains attached and interferes with RISC loading.
Common methods include calcein leakage assays (measuring release of a fluorescent dye from endosomes), galectin recruitment assays (detecting galectin proteins that bind to damaged endosomal membranes), and confocal microscopy with endosomal markers to quantify diffuse cytoplasmic vs punctate endosomal fluorescence. Functional readouts such as dose-response gene silencing also provide an indirect but biologically meaningful measure of successful cytoplasmic delivery.
References
